ADVERTISEMENT
Kevin Punie, MD, Discusses Novel Therapy Significantly Improving QOL Over SOC in 2L+ mTNBC
Kevin Punie, MD, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease, presented at the ESMO Congress.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement